Carl Zeiss Meditec AG (VIE:AFX)
Austria · Delayed Price · Currency is EUR | Market Cap | 2.51B -51.7% |
| Revenue (ttm) | 2.20B +5.9% |
| Net Income | 120.61M -23.2% |
| EPS | 1.40 -21.2% |
| Shares Out | n/a |
| PE Ratio | 20.84 |
| Forward PE | 17.21 |
| Dividend | 0.55 (2.09%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | n/a |
| Average Volume | 313 |
| Open | 25.92 |
| Previous Close | 28.68 |
| Day's Range | 25.92 - 26.12 |
| 52-Week Range | 22.82 - 65.65 |
| Beta | n/a |
| RSI | 64.07 |
| Earnings Date | May 12, 2026 |
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and p... [Read more]
Financial Performance
In fiscal year 2025, Carl Zeiss Meditec AG's revenue was 2.23 billion, an increase of 7.82% compared to the previous year's 2.07 billion. Earnings were 141.21 million, a decrease of -20.99%.
Financial StatementsNews
Carl Zeiss Meditec AG Earnings Call Transcript: Q2 2026
Revenue and profitability declined in H1 due to FX headwinds and weak China IOL sales. The Profit Up Program targets over EUR 200 million in annual profit improvements by 2028/2029, with midterm EBITDA margin above 15%. H2 is expected to show stronger results.
EQS-RPT: Carl Zeiss Meditec AG: Release according to Article 111c of the AktG [the German Stock Corporation Act] with the objective of Europe-wide distribution
EQS Related Party Transactions announcement: Carl Zeiss Meditec AG / Release of an announcement according to Article 111c of the AktG [the German Stock Corporation Act] Carl Zeiss Meditec AG: Release ...
Carl Zeiss Meditec AG Profit Retreats In Q2
JENA (dpa-AFX) - Carl Zeiss Meditec AG (CZMWF.PK) revealed earnings for second quarter that Dropped, from the same period last yearThe company's earnings came in at EUR19.569 million, or EUR0.22 p...
EQS-Adhoc: Carl Zeiss Meditec AG: Revenue and earnings declined in the first half of fiscal year 2025/26 – Comprehensive package of measures announced to safeguard future growth and earnings potential – Updated
EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Results / Half year/Forecast / Full year Carl Zeiss Meditec AG: Revenue and earnings declined in the first half of fiscal year 2025/26 – Comprehensive ...
EQS-AFR: Carl Zeiss Meditec AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Carl Zeiss Meditec AG / Preliminary announcement on the disclosure of financial statements Carl Zeiss Meditec AG: Preliminary announcement of the public...
Carl Zeiss Meditec AG Earnings Call Transcript: Q1 2026
Revenue and profitability declined sharply year-over-year due to currency headwinds, unfavorable product mix, and regulatory challenges in China. Guidance was suspended amid increased competition and market uncertainty, with a significant one-off impact expected in Q2.
Carl Zeiss Meditec AG Earnings Call Transcript: Q4 2025
Revenue grew 7.8% to EUR 2.23 billion with strong order entry and record recurring revenue. EBITDA margin improved to 11.6% despite FX and tariff headwinds. Guidance for 2025-2026 targets mid-single-digit revenue growth and a 12.5% EBITDA margin, with midterm ambitions of 16%-20% margin.
Carl Zeiss Meditec AG Earnings Call Transcript: Q3 2025
Order entry and revenue grew strongly, with recurring revenue at a record high and adjusted EBITDA margin improving. U.S. tariffs and FX headwinds weighed on net income, but product launches and D.O.R.C. integration supported growth. Guidance remains for moderate revenue growth and stable margins.
Carl Zeiss Meditec AG Earnings Call Transcript: Q2 2025
Revenue grew 10.9% to EUR 1.051 billion with strong order entry and recurring revenue now at 50%. EBITDA stabilized, but net income and EPS declined. Guidance is unchanged amid macro and tariff risks, with new product launches and CEO transition underway.
Carl Zeiss Meditec AG Earnings Call Transcript: Q1 2025
Revenue grew 3.2% year-over-year to EUR 491 million, but organic sales declined 7.3% due to tough comparisons and weak China demand. EBITDA margin fell to 7.2%, while order entry rebounded strongly. Guidance remains for moderate growth, with new product launches and DORC integration expected to support recovery.
Carl Zeiss Meditec AG Earnings Call Transcript: Q4 2024
Revenue and profit declined in 2023-2024 due to weak investment climate and consumer sentiment, but recurring revenue and order entry improved with the DORC acquisition. Moderate growth and stable margins are expected for 2024-2025, with cost control and new product launches providing potential upside.
Carl Zeiss Meditec AG Earnings Call Transcript: Q3 2024
Revenue and profit declined year-over-year due to weak investment climate and consumer sentiment, with EBIT down 34% and net income down 42%. DORC integration contributed to results, and order intake stabilized, but management expects to achieve the lower end of adjusted EBIT guidance.
Carl Zeiss Meditec AG Earnings Call Transcript: Q2 2024
Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market
ZEISS secures regulatory approvals to acquire D.O.R.C.; companies now shift focus to integration implementation, fueling world-class innovation, and driving market expansion strategy for ophthalmic me...
Carl Zeiss Meditec AG Earnings Call Transcript: Q1 2024
Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment JENA, Germany , Dec. 15, 2023 /PRNewswire/ -- Carl ...